Dr. Gerald Maguire: Pagoclone Phase IIB Trial and Updates (Episode 90)

Download | Duration: 01:15:52

Gerald Maguire, M.D., joins Peter Reitzes and Eric Jackson to discuss Pagoclone and the Pagolcone Phase IIB trial. Dr. Maguire may be contacted at The Kirkup Center for the Medical Treatment of Stuttering  which includes Maguire's telemedicine program. The Center provides evaluations to individuals throughout the globe. As a non-profit center, scholarships are available to individuals who stutter who have limited means as well. Dr. Maguire may also be contacted at his University's Treatment Center. Email gerald.maguire@uci.edu.

          

Dr. Maguire has been a featured guest on:
Check out this article by Dr. Maguire, New Drugs for Stuttering May Be on the Horizon and read about Dr. Maguire's keynote address at the National Stuttering Association's 2006 annual conference. Click here to view the patent for Pagoclone.

 del.icio.us  Stumbleupon  Technorati  Digg 

Posted by StutterTalk at 2/4/2009 9:33 PM
Categories: uncategorized
Tags: stuttertalk stuttering stammer stuttering treatment stuttering help stutter talk stammering stutter
 
Trackbacks
Trackback specific URL for this entry
  • No trackbacks exist for this entry.
Comments
Display comments as (Linear | Threaded)
Page: 1 of 1
  • 2/16/2009 4:34 PM Sam Dagher wrote:
    Maguire is great!

    Doing justice to premise "if patients in faraway places can’t come to his UC Irvine Medical Center office for treatment, we bring it to them", he will be in Brazil in early April.
    Reply to this
    1. 2/16/2009 4:45 PM StutterTalk wrote:
      Thanks for writing StutterTalk. It is cool that Dr. Maguire will be in Brazil.

      take care,

      Peter

      Reply to this
  • 6/3/2009 11:43 AM David Coppes wrote:
    Does pagaclone help resist the urge to drink alcohol?
    Reply to this

Page: 1 of 1
Leave a comment

Submitted comments will be subject to moderation before being displayed.

 Enter the above security code (required)

 Name (required)

 Email (will not be published) (required)

 Website

Your comment is 0 characters limited to 3000 characters.